Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Key Points

• Immix Biopharma reported a quarterly earnings loss of ($0.22) per share, missing expectations by $0.01.
• The company's stock price remained stable at $2.39, with a market cap of $66.63 million.
• Analyst ratings include a "buy" rating from HC Wainwright with a target price of $7.00, while Wall Street Zen upgraded the stock to a "hold" rating.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.01), Zacks reports.

Immix Biopharma Stock Performance

Shares of Immix Biopharma stock traded down $0.17 on Thursday, reaching $2.16. 71,765 shares of the stock were exchanged, compared to its average volume of 164,635. The firm's 50 day moving average is $2.53 and its 200-day moving average is $2.08. Immix Biopharma has a one year low of $1.26 and a one year high of $3.20. The firm has a market cap of $62.28 million, a PE ratio of -2.81 and a beta of 0.28.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on IMMX shares. Wall Street Zen upgraded shares of Immix Biopharma to a "hold" rating in a research note on Friday, June 27th. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Immix Biopharma in a report on Wednesday, June 4th.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.